ScreenerHero

SPTX Seaport Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · seaporttx.com
17.91USD-0.11%Mkt Cap: 958.73M $P/E: —

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leverag…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap958.73M USD
Enterprise Value661.53M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-74.88M USD
Revenue/Share—
Last Price17.91 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees58
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.75
PEG—
EV/EBITDA-4.60
EV/Revenue—
P/S—
P/B2.20
EPS (TTM)-5.44
EPS (Forward)-2.57
52W Range
14.8523% of range28.38
52W High28.38 USD
52W Low14.85 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE80.91%
ROA-30.07%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.94M USD
CapEx (TTM)356.00K USD
FCF Margin—
FCF Yield—
Net Debt-268.29M USD
Net Debt/EBITDA1.87
Balance Sheet
Debt/Equity-0.05
Current Ratio18.00
Quick Ratio17.75
Book Value/Sh7.89 USD
Cash/Share5.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)38.29 USD
Upside (mean)+113.8%
Target Range30.00 USD – 50.00 USD
30.00+113.8% to mean50.00
# Analysts7
Ownership
Shares Out.53.53M
Float18.43M
Insiders35.14%
Institutions70.95%
Short Interest
Short Ratio22.9d
Short % Float6.18%
Short % Out.5.88%
Shares Short3.15M
Short (prev mo.)3.01M
Technical
SMA 5022.54 (-20.5%)
SMA 20020.36 (-12.0%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)262.06K
Avg Vol (10d)244.78K
Technical Indicators
RSI (14)36.7
MACD-1.3898
MACD Signal-1.0922
MACD Hist.-0.2976
BB Upper24.69 USD
BB Middle20.57 USD
BB Lower16.44 USD
BB Width40.12%
ATR (14)1.742 USD
Vol Ratio (20d)0.56x